Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Alexander Monto, MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    AddressVAMC
    San Francisco CA 94121
    Phone415-221-4810x2958
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, San FranciscoResidency School of Medicine

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Waldron PR, Belitskaya-Lévy I, Chary A, Won J, Winters M, Monto A, Ryan J, Lazzeroni LC, Holodniy M. Genetic Variation in the IL-6 and HLA-DQB1 Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection. J Immunol Res. 2016; 2016:6530436. PMID: 27340680.
        View in: PubMed
      2. Fraenkel L, Lim J, Garcia-Tsao G, Reyna V, Monto A, Bridges JF. Variation in Treatment Priorities for Chronic Hepatitis C: A Latent Class Analysis. Patient. 2016 Jun; 9(3):241-9. PMID: 26518200.
        View in: PubMed
      3. Cozen ML, Ryan JC, Shen H, Cheung R, Kaplan DE, Pocha C, Brau N, Aytaman A, Schmidt WN, Pedrosa M, Anand BS, Chang KM, Morgan T, Monto A. Improved Survival Among all Interferon-a-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. Dig Dis Sci. 2016 Jun; 61(6):1744-56. PMID: 27059981.
        View in: PubMed
      4. Fraenkel L, Lim J, Garcia-Tsao G, Reyna V, Monto A. Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? J Clin Gastroenterol. 2016 Mar; 50(3):252-7. PMID: 26166145.
        View in: PubMed
      5. Saxena V, Monto A, Terrault N. Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals - authors' reply. Aliment Pharmacol Ther. 2014 Jun; 39(12):1428. PMID: 24849150.
        View in: PubMed
      6. Somsouk M, To'o K, Ali M, Vittinghoff E, Yeh BM, Yee J, Monto A, Inadomi JM, Aslam R. Esophageal varices on computed tomography and subsequent variceal hemorrhage. Abdom Imaging. 2014 Apr; 39(2):251-6. PMID: 24366107; PMCID: PMC3979277.
      7. Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther. 2014 May; 39(10):1213-24. PMID: 24654657; PMCID: PMC4385588.
      8. Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, Corvera CU, Monto A. Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford). 2014 Aug; 16(8):758-67. PMID: 24467780; PMCID: PMC4113259.
      9. Zissen MH, Wang ZJ, Yee J, Aslam R, Monto A, Yeh BM. Contrast-enhanced CT quantification of the hepatic fractional extracellular space: correlation with diffuse liver disease severity. AJR Am J Roentgenol. 2013 Dec; 201(6):1204-10. PMID: 24261358.
        View in: PubMed
      10. Cozen ML, Ryan JC, Shen H, Lerrigo R, Yee RM, Sheen E, Wu R, Monto A. Nonresponse to interferon-a based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One. 2013; 8(4):e61568. PMID: 23637856; PMCID: PMC3636226.
      11. Rempel H, Sun B, Calosing C, Abadjian L, Monto A, Pulliam L. Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. PLoS One. 2013; 8(2):e55776. PMID: 23437063; PMCID: PMC3578833.
      12. Yee RM, Lehil MS, Rongey C, Shen H, Cozen ML, Monto A, Ryan JC. Impaired lymphocyte reactivity measured by immune function testing in untransplanted patients with cirrhosis. Clin Vaccine Immunol. 2013 Apr; 20(4):526-9. PMID: 23389930; PMCID: PMC3623409.
      13. Sun B, Abadjian L, Rempel H, Monto A, Pulliam L. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection. J Acquir Immune Defic Syndr. 2013 Feb 1; 62(2):190-6. PMID: 23187938; PMCID: PMC3587125.
      14. Monto A, Ryan J. Is IL28B genotype associated with more than one aspect of viral clearance? Hepatology. 2012 Dec; 56(6):2414-6. PMID: 23212777.
        View in: PubMed
      15. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012 May; 107(5):669-89; quiz 690. PMID: 22525303.
        View in: PubMed
      16. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Günthard HF, Wong JK. Role of retroviral restriction factors in the interferon-a-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):3035-40. PMID: 22315404; PMCID: PMC3286922.
      17. Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, Schneider G, Sarrazin C. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol. 2011 Oct; 52(2):133-7. PMID: 21803650.
        View in: PubMed
      18. Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Dig Dis Sci. 2011 Aug; 56(8):2439-48. PMID: 21633833.
        View in: PubMed
      19. Bacchetti P, Boylan R, Astemborski J, Shen H, Mehta SH, Thomas DL, Terrault NA, Monto A. Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One. 2011; 6(5):e20104. PMID: 21637766; PMCID: PMC3103523.
      20. Babik JM, Cohan D, Monto A, Hartigan-O'Connor DJ, McCune JM. The human fetal immune response to hepatitis C virus exposure in utero. J Infect Dis. 2011 Jan 15; 203(2):196-206. PMID: 21288819; PMCID: PMC3071071.
      21. Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods. 2011 Mar; 172(1-2):27-31. PMID: 21182871.
        View in: PubMed
      22. Russell JS, Sawhney R, Monto A, Nanavati S, Davoren JB, Aslam R, Corvera CU. Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center. Am J Surg. 2010 Nov; 200(5):659-64. PMID: 21056149.
        View in: PubMed
      23. Bacchetti P, Boylan RD, Terrault NA, Monto A, Berenguer M. Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant. Int J Biostat. 2010; 6(1):Article 7. PMID: 20305705; PMCID: PMC2836212.
      24. Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, Pawlotsky JM, McHutchison JG, Jacobson IM. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol. 2010 May; 105(5):989-1004; quiz 988, 1005. PMID: 20087331.
        View in: PubMed
      25. Chapko MK, Yee HS, Monto A, Dominitz JA. Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. Vaccine. 2010 Feb 17; 28(7):1726-31. PMID: 20044051.
        View in: PubMed
      26. Tsui JI, Whooley MA, Monto A, Seal K, Tien PC, Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail. 2009 Jun; 15(5):451-6. PMID: 19477406; PMCID: PMC2782758.
      27. Sewell JL, Stick KM, Monto A. Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy. Eur J Gastroenterol Hepatol. 2009 Feb; 21(2):225-9. PMID: 19212213; PMCID: PMC2744965.
      28. Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC, Monto A, Rossi SJ, Sulkowski MS. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol. 2008 Nov; 103(11):2757-65. PMID: 18684176.
        View in: PubMed
      29. Monto A, Currie S, Wright TL. Liver disease in injection drug users with hepatitis C, with and without HIV coinfection. J Addict Dis. 2008; 27(2):49-59. PMID: 18681191.
        View in: PubMed
      30. Chang TT, Sawhney R, Monto A, Davoren JB, Kirkland JG, Stewart L, Corvera CU. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford). 2008; 10(6):405-11. PMID: 19088925; PMCID: PMC2597312.
      31. Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, Kim M, Shen H, Monto A. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend. 2008 Jan 11; 93(1-2):148-54. PMID: 17977668.
        View in: PubMed
      32. Seal KH, Monto A, Dove L, Shen H, Vittinghoff E, Tracy D, Miller E, Lau E, Wright TL. The association of human immunodeficiency virus infection with spontaneously resolved hepatitis C virus infection and level of viremia among injection drug users. Dig Dis Sci. 2007 Dec; 52(12):3423-30. PMID: 17443407.
        View in: PubMed
      33. Hui CK, Lau E, Monto A, Kim M, Luk JM, Poon RT, Leung N, Lo CM, Fan ST, Lau GK, Wright TL. Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation. Am J Transplant. 2006 Jul; 6(7):1600-8. PMID: 16827860.
        View in: PubMed
      34. Monto A, Kakar S, Dove LM, Bostrom A, Miller EL, Wright TL. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am J Gastroenterol. 2006 Jul; 101(7):1509-15. PMID: 16863554.
        View in: PubMed
      35. Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Abar OT, Yee L, Chokkalingam AP, Schrodi SJ, Chan J, Catanese JJ, Leong DU, Ross D, Hu X, Monto A, McAllister LB, Broder S, White T, Sninsky JJ, Wright TL. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology. 2006 May; 130(6):1679-87. PMID: 16697732.
        View in: PubMed
      36. Dove L, Phung Y, Bzowej N, Kim M, Monto A, Wright TL. Viral evolution of hepatitis C in injection drug users. J Viral Hepat. 2005 Nov; 12(6):574-83. PMID: 16255758.
        View in: PubMed
      37. Hui CK, Lau E, Wu H, Monto A, Kim M, Luk JM, Lau GK, Wright TL. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol. 2006 Feb; 35(2):185-92. PMID: 16103008.
        View in: PubMed
      38. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology. 2005 Aug; 42(2):310-6. PMID: 16025515.
        View in: PubMed
      39. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004 Mar; 39(3):826-34. PMID: 14999703.
        View in: PubMed
      40. Hui CK, Monto A, Belaye T, Lau E, Wright TL. Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut. 2003 Nov; 52(11):1644-8. PMID: 14570736; PMCID: PMC1773858.
      41. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002 Sep; 36(3):729-36. PMID: 12198667.
        View in: PubMed
      42. Monto A. Hepatitis C and steatosis. Semin Gastrointest Dis. 2002 Jan; 13(1):40-6. PMID: 11944633.
        View in: PubMed
      43. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol. 2001 Oct; 28(5):441-9. PMID: 11685737.
        View in: PubMed
      44. Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. J Med Virol. 1999 Aug; 58(4):353-8. PMID: 10421401.
        View in: PubMed
      Alexander's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP